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Summary The 3H-thymidine labelling index (3H-dT LI) of cell suspensions from fresh material and the flow
cytometric S-phase (FCM-S) of nuclei recovered from paraffin blocks were determined on the same pathologic
lymph node specimen for 190 non-Hodgkin's lymphomas (NHLs). FCM-S was defined by a planimetric
method and by an optimization procedure. Poor correlation coefficients were observed among the three cell
kinetic variables. All three cell kinetic variables were significant indicators of 8-year survival and median
survival time. The life-regression procedure evidenced a significant relative contribution of 3H-dT LI and
FCM-S, thus suggesting a different biologic meaning of the two cell kinetic variables. This finding was further
supported by evidence that simultaneous use of 3H-dT LI and FCM-S can identify groups of patients with
different survival better than when either modality is used alone. Multivariate analysis indicated that the risk
groups as defined by cell kinetic variables are predictors of survival even in the presence of established factors
such as histology and stage.
The prognostic relevance of cell kinetics in malignant non-
Hodgkin's lymphomas (NHLs) has been the subject of study
for several decades. Cell kinetic studies have consistently
shown that 3H-thymidine labelling index (3H-dT LI) is an
indicator of long-term clinical outcome (Brandt et al., 1981;
Costa et al., 1981; Kvaloj et al., 1985), independently of
prognostic factors such as histopathology and stage (Silves-
trini et al., 1989).
More recently, we showed that the use of bromodeox-
yuridine (BUdR) on NHL specimens gives labelling index
values superimposable to those obtained with 3H-thymidine
(Silvestrini et al., 1988). However, both approaches are based
on the incorporation of DNA metabolic precursors and
therefore imply the availability of fresh and viable tumour
material. Such a requirement cannot always be satisfied
when, as often happens, patients are referred with pathologic
material already fixed and another biopsy is not ethically
justified or easily obtainable. Moreover, determination of
3H-dT LI or BUdR LI is limited to prospective collection of
fresh biopsies and precludes retrospective analysis ofparaffin-
embedded samples from series of patients with a long follow-
up.
Several studies have shown that the flow cytometric S-
phase cell fraction (FCM-S) is a discriminant of clinical
outcome in NHL patients (Braylan et al., 1980; Scarffe &
Crowther, 1981; Roos et al., 1985; Christensson et al., 1986;
Lenner et al., 1987; Griffin et al., 1988; Grierson et al., 1990;
Rehn et al., 1990; Joensuu et al., 1990). Flow cytometric
analysis is an automatic and quick method to measure the
S-phase cell fraction, and an advantage is that stocked
paraffin blocks can be used for retrospective analysis.
The present study compared the results obtained when the
S-phase cell fraction was measured by autoradiography and
by flow cytometry with two mathematical models, i.e., a
planimetric method and an optimisation procedure. More-
over, through univariate and multivariate analyses we defined
the prognostic power for survival of cell kinetics and clinical
and pathologic variables determined in parallel on the same
patients.
Materials and methods
Case series
Biopsies were obtained from 190 patients with NHLs at the
National Cancer Institute of Milan between 1974 and 1989.
The 3H-dT LI was determined on fresh tissue specimens, and
flow cytometric S-phase was determined on the same biopsy
sample from paraffin-embedded blocks. All patients were
pathologically staged and classified according to the Ann
Arbor Staging System (Carbone et al., 1971). Treatment was
decided according to different prospective protocols (Monfar-
dini et al., 1980; Monfardini et al., 1984; Bajetta et al., 1988;
Tondini et al., 1991) or to the best standard therapy.
Histologic specimens were retrospectively reviewed and
classified according to the Working Formulation for clinical
usage according with The Non-Hodgkin's Lymphoma Path-
ologic Classification Project (1982). The new National Cancer
Institute clinical distinction (NCI system) between indolent
lymphoma (small lymphocytic; follicular, small cleaved cells;
follicular, mixed; diffuse, small cleaved cells) and aggressive
lymphoma (follicular, large cell; diffuse, mixed; diffuse, large
cell; diffuse, immunoblastic) was applied for prognostic ana-
lysis (De Vita et al., 1989; Urba et al., 1990).
3H-dT LI
3H-dT LI was determined on cell suspensions obtained by
mechanical disaggregation of lymph node material as pre-
viously described (Costa et al., 1981). Briefly, 6 x 106 cells
were incubated with 3H-thymidine (41.Ci; specific activity,
25 Ci mmol 1; Radiochemical Centre, Amersham, UK) for
1 h at 37°C. Autoradiography was performed according to
the stripping film (ARI0 Kodak) technique. The 3H-dT LI
was determined on the entire cell population by scoring
5,000-10,000 cells from different cytospins for each tumour.
FCM-S
Flow cytometric analysis was performed on cells recovered
from paraffin-embedded specimens and fixed in formalin (132
cases) or Zenker's solution (58 cases). Tumor sample ade-
quacy was assessed at the microscope on hematoxylin-eosin-
stained sections adjacent to those used for flow cytometric
analysis and was verified by a pathologist (R.G.).
The technique of Hedley et al. (1983) with minor
modifications was used. The nuclei suspension was stained
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with a solution containing propidium iodide (Calbiochem,
Boehring, Corp., San Diego, CA) at the concentration of
50 rmml-' in H20, 0.05% Nonidet P40 (Calbiochem) and
RNase (Type IA, from bovine pancreas, Sigma).
DNA analysis was performed using a FACScan flow
cytometer (Becton-Dickinson, San Jose, CA), and a mini-
mum of 30,000 events was acquired on a single-parameter
256-channel integrated fluorescence histogram. Since the use
of paraffin-embedded specimens does not allow the use of an
internal standard to determine the position of a diploid GO/,
population of cells (Schute et al., 1985), an aneuploid cell
population was considered to be present only if two distinct
Go/, peaks were evident. In such DNA profiles, the DNA
index of the aneuploid population was calculated by dividing
the mean fluorescence channel of the Go/, peak with the
higher intensity by the mean fluorescence channel of the Go/,
peak with the lower intensity. A lower median CV was
observed for formalin-fixed (4.9%) than for Zenker-fixed
specimens (8.9%). Only DNA profiles with a Go/, peak CV
less than 8% were considered evaluable, and this criterion
was fulfilled in 155 of the original 190 cases.
FCM-S was computed by two mathematical models: a
planimetric method (RFIT, Becton Dickinson) and an opti-
misation procedure (Lampariello & Del Bino, 1988). Accor-
ding to the first model the S phase was calculated from a
rectangle, where the height of the rectangle is the average
height of mid S phase. For aneuploid tumors, the S-phase
fraction of the aneuploid population alone was calculated
[i.e. (number of aneuploid S-phase cells/total number of
aneuploid cells) x 100]. The second model represents an
optimisation procedure to process DNA histograms contain-
ing up to two cell populations and includes an exponential
function to subtract background debris. An objective mea-
sure of goodness of fit is obtained by computing the chi-
square error index. In our experience, chi-square values lower
than 3 corresponded to nearly exact fits, as judged by visual
inspection.
Statistical analysis
Spearman's correlation coefficient (Hajek & Sidak, 1967) was
used to compare S-phase percentages obtained by the two
models and to investigate the relationship between FCM-S
and 3H-dT LI. The differences in cell kinetics in the various
clinico-pathologic subsets were analysed by means of the
Wilcoxon rank-sum test.
The role of each of the prognostic variables (univariate
analysis) and their joint effect (multivariate analysis) were
evaluated by resorting to a Weibull regression model. In this
model each regression coefficient (p) is recognisable as the log
of the hazard ratio and it is constant with time. For each
variable, the 'unadjusted' hazard ratio and its 95%
confidence interval were estimated using the putative 'best
prognosis' as reference category. To investigate the joint
prognostic relevance of the kinetic variables (3H-dT LI,
planimetric and optimisation FCM-S), the 'adjusted' hazard
ratios were estimated by resorting to a multiple regression
model containing the three variables. The parsimonious
regression model was obtained by means of a backward
elimination procedure.
Results
FCM-S was computed by the planimetric method and the
optimisation procedure on 149 of 155 cases with evaluable
DNA histograms. Similar median values (3.7% and 4.0%),
ranges and exponential distributions were observed for 3H-dT
LI and FCM-S determined by the optimisation procedure,
which implies subtraction of debris contamination. A higher
median FCM-S value (12%), as expected, and a log-normal
distribution were observed by using the planimetric method
without background subtraction.
Statistically significant correlation coefficients between the
3H-dT LI values and the FCM-S values obtained by the two
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Figure 1 Relationship between cell kinetic variables. a, 3H-dT LI
vs planimetric FCM-S; b, 3H-dT LI vs optimisation FCM-S; c,
planimetric vs optimisation FCM-S. r, = Spearman's correlation
coefficient.
quantification approaches were observed. However, the strength
of the association appeared to be rather poor (Figure la,b).
A significant correlation with a somewhat higher correlation
coefficient (r, = 0.70) was also observed between the FCM-S
data pairs obtained with or without background subtraction
(Figure lc). Cell kinetics, expressed in the three different
ways, was consistently related to histology as defined by the
NCI system and unrelated to stage or patient's age. Con-
versely, FCM S-phase fraction, but not 3H-dT LI, was
related to DNA ploidy (Table I).
Survival analysis was performed on the 138 patients with
complete kinetic evaluation and follow-up information. The
median value of each cell kinetic variable was used as the
cutoff between slowly and rapidly proliferating NHLs. Uni-
variate analysis showed that all three variables were cor-
related to 8-year survival but with a different discriminant
power. In fact, survival curves were more diversified for the
two kinetic subgroups as defined by 3H-dT LI than for those
defined by FCM-S (Figure 2). Patients with high 3H-dT LI
tumours had about a four-fold shorter median survival than
those with low 3H-dT LI tumours (Table II). Conversely, the
difference was only about two-fold when the FCM-S deter-
mination was considered. These findings were also reflected
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Table I Relationship between cell kinetic variables and biologic, clinico-pathologic features
3H-dT LI (%) FCM-S (median, %)
P Optimisation P Planimetric P
Median value procedure value method value
Working Formulationa
Indolent lymphoma 2.0 <001 3.0 <0.001 20.3 .0 Agressive lymphoma 9.6 <0.001 10.3 203
Stage
I-II 4.5 3.8 12.1
III-IV 3.5 ns 4.5 ns 12.2 ns
Patient's age
<60 yrs 3.6 4.4 11.1
>60 yrs 5.1 ns 4.ns 13.0 ns
DNA ploidy
Diploid 4.6 ns3.8 0.5 10.8 <00 Aneuploid 35 ns 5.8 0. 20.0 <0.001
aAccording to NCI system.
Table II Prognostic relevance for survival of cell kinetic
variables
Median 95%
survival Hazard Confidence Pb
(mo) ratio interval value
3H-dT LI
< 4%a 80 2.38 1.67-3.39 0.001
>4% 17
FCM-S
Planimetric
method
> 12%a 62 1.96 1.21-3.16 0.006 >12% 25
Optimisation
procedure
<4%a 26 1.62 0.98-2.68 0.05
aReference category. bBased on Wald statistics.
by the different hazard ratios observed when considering the
three different variables (Table II). Relative influence on
survival of the three cell kinetic variables was assessed by a
multiple regression analysis (Table III). Using a backward
method for regression, the value of FCM-S according to the
optimisation procedure was removed from the model, leaving
3H-dT LI and planimetric FCM-S in the final step. These two
cell kinetic variables retained independent prognostic values
even though they were characterised by a different hazard
ratio and effect on long-term survival (Table III). Finally, we
evaluated whether information provided by these two cell
kinetic variables could identify groups of patients with
different survival probabilities better than either modality
(I)
alone. Plots of the survival curve obtained by the regression
model identified three groups of patients with different sur-
vival probabilities. Survival curves estimated by the re-
gression model for each group showed that patients with two
unfavourable cell kinetic variables (high 3H-dT LI, high
FCM-S) did very poorly, with a median survival of only 12
months (Figure 3). In contrast, the median survival of
patients with favourable variables (low 3H-dT LI, low FCM-
S) was 80 months, and the presence of only one risk factor
identified a group with an intermediate median survival of 59
months. Multiple regression analysis of cell kinetic variables,
indolent and aggressive lymphomas as defined by the NCI
system, and Ann Arbor stage (Table IV) showed that in the
present series of patients cell proliferation index retained its
prognostic relevance.
Discussion
The proliferation indices, as defined by flow cytometric and
autoradiographic methods, have shown their relevance as
prognostic indicators in NHLs (Braylan et al., 1980; Brandt
et al., 1981; Costa et al., 1981; Scarffe & Crowther 1981;
Kvaloj et al., 1985; Roos et al., 1985; Christensson et al.,
1986; Lenner et al., 1987; Griffin et al., 1988; Silvestrini et al.,
1989; Grierson et al., 1990; Rehn et al., 1990; Joensuu et al.,
1990) as well as in other human malignancies (Volm et al.,
1985; Volm et al., 1988; Costa et al., 1990; McGuire et al.,
1990; O'Reilly et al., 1990; Silvestrini et al., 1990). However,
cell kinetic variables have been usually studied independently
on different series of patients, thus preventing a clear com-
parison between the different methods. The present study
allowed a direct comparison, on the same biopsy sample, of
Years
Figure 2 Eight-year survival as a function of cell kinetic variables. a, 3H-dT LI; b, planimetric FCM-S; c, optimisation FCM-S.
(---) slowly proliferating NHLs; ( ) rapidly proliferating NHLs.CELL KINETICS AND PROGNOSIS IN NHLS 683
Table HI Multiple regression analysis of cell kinetic variables
95%
P Hazard confidence
Model Chi squarea value ratio interval
Complete
3H-dT LI 5.50 0.02 1.83 1.11-3.04
(>4% vs <4%)
FCM-S
Planimetric method 3.26 0.07 1.65 0.96-2.85
(> 12% vs < 12%)
Optimisation procedure 0.23 n.s. 1.14 0.66-1.97
(>4% vs <4%)
Final
3H-dT LI 8.04 0.005 1.96 1.23-3.13
Planimetric FCM-S 3.96 0.046 1.63 1.01-2.63
aBased on Wald statistics.
2o Noriskfactors (I)~~~~~~~~~~~N-
1 risk factor
2 risk factors
0 1 2 3 4 5 6 7 8
Years
Figure 3 Eight-year survival as a function of combined 3H-dT
LI and FCM-S. Low proliferation index (43 patients): 3H-dT LI
< 4% and FCM-S < 12%; intermediate proliferation index (46
patients): 3H-dT LI < 4% and FCM-S > 12%, or 3H-dT LI
>4% and FCM-S < 12%; high proliferation index (50 patients):
3H-dT LI >4% and FCM-S >12%.
the interrelationship and of the relative contribution as prog-
nostic indicators of 3H-dT LI and of FCM-S.
The study showed the high feasibility, which was favoured
by the high frequency of diploid NHLs (about 70%), of
FCM-S determination for paraffin-embedded specimens. More-
over, in agreement with the results of several studies (Griffin et
al., 1988; Grierson et al., 1990; Joenssu et al., 1990), the clinical
relevance of ploidy was not found (data not shown) and the
relevance of FCM-S as a prognostic indicator for survival was
confirmed. The results also showed a greater reliability of a
planimetric method than of a more sophisticated optimisation
procedure with background subtraction to quantify the S-phase
cell fraction. We interpret these findings as evidence that
exponential debris subtraction could be of greater biologic
relevance in other tumor systems than in NHLs. Although
debris and contaminating non-neoplastic populations both inter-
fere with FCM-S quantifications, the relative artifactual contri-
bution of each alteration of a true neoplastic proliferative cell
fraction is not known. The effect of both variables most likely
varies considerably from case to case, depending on a number of
factors intrinsic to the individual tumour and technical in
nature.
Table IV Multiple regression analysis for survival
P
Chi squarez value
3H-dT LI, FCM-S 7.12 <0.05
Stage 2.31 ns
Working Formulationb 1.04 ns
aBased on Wald statistics. bAccording to NCI system.
Furthermore, the present study suggests that the different
accuracy of flow cytometric or autoradiographic methods in
predicting clinical outcome is probably due to a different
biologic meaning of the two cell kinetic variables. This assump-
tion is supported by their difference in identifying proliferating
cells. In fact, 3H-dT as a precursor of thymine is therefore a
specific precursor ofDNA and it has a functional activity, i.e., it
measures the fraction ofcycling S-phase cells. As regards FCM-
S, such a determination does not discriminate between actually
DNA synthesising cells and those with an S-phase equivalent
DNA content but quiescent. Moreover, the relation observed
between DNA ploidy and the S-phase cell fraction defined on
the basis of nuclear DNA content and the lack of a relation
with the S-phase cell fraction defined by DNA precursor incor-
poration could indicate that the two cell kinetic variables are
partially complementary. In fact, in combination they accurately
identify subgroups at different risk.
Multiple regression analysis including cell kinetic variables,
histology (as defined by the NCI system or by the three subsets
of the Working Formulation), and stage indicated the relevance
of the association of 3H-dT LI and FCM-S in predicting sur-
vival. However, owing to the heterogeneity ofour population of
NHL patients and the different therapeutic approaches used
during the study period, we do not feel that the present study
can define the correlation between kinetic variables and com-
plete remission. Therefore, the precise role ofkinetic variables in
defining survival should be interpreted with caution. These
findings should be confirmed by prospective studies on adequate
series of patients homogeneous for tumour histology and treat-
ment. Such an analysis should necessarily include other biologic
factors of established prognostic relevance, such as LDH and
P2-microglobulin, number of extranodal sites and presence of
bulky disease.
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